Metastatic urothelial cancer showing an efficacy by low-dose cisplatin.
A 69-year-old man who had developed multiple distant metastases on retrocaval lymph nodes after four courses of Methotraxate, Vinblastine, Adriamycin, Cisplatin (MVAC) chemotherapy was successfully treated by intravenous infusion of low-dose cisplatin (CDDP) (10 mg/time, once per week) and oral administration of 600 mg/day 5'-deoxy-5-fluorouridine (5'-DFUR), a pro-drug of 5-FU, in an outpatient setting. A partial response (62% reduction rate) was confirmed by abdominal computed tomography (CT) scan after 7 months. Although the CDDP dosage had been reduced to 5 mg/week 1 year previously, the tumor was still reducing in size in November 2000. Combination therapy of 5'-DFUR with low-dose CDDP could become an option for advanced bladder cancer that compromises the patient's quality of life, especially when used in an outpatient setting.
Matsuyama
Hideyasu
H
Department of Urology, Yamaguchi Red Cross Hospital, Japan. hidde@ymg.urban.ne.jp
Yamakawa
Gen-Ichiro
G
Hirata
Hiroshi
H
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage*; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008207:Lymphatic Metastasis; D008297:Male; D010045:Outpatients; D011859:Radiography; D014516:Ureteral Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D019459:Urothelium
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005467:Floxuridine; D002945:Cisplatin; C025034:doxifluridine